Literature DB >> 27466420

Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion.

Eunseon Ahn1, Ben Youngblood2, Junghwa Lee1, Judong Lee1, Surojit Sarkar3, Rafi Ahmed4.   

Abstract

UNLABELLED: PD-1 is an inhibitory receptor that has a major role in T cell dysfunction during chronic infections and cancer. While demethylation of the PD-1 promoter DNA is observed in exhausted T cells isolated from chronically infected individuals, little is known about when this stable demethylation of PD-1 promoter DNA is programmed during the course of a chronic infection. To assess if PD-1 promoter DNA demethylation is impacted by prolonged stimulation during effector phase of chronic infection, we adoptively transferred virus-specific day 8 effector CD8 T cells from mice infected with lymphocytic choriomeningitis virus (LCMV) clone 13 into recipient mice that had cleared an acute infection. We observed that LCMV-specific CD8 T cells from chronically infected mice maintained their surface expression of PD-1 even after transfer into acute immune mice until day 45 posttransfer. Interestingly, the PD-1 transcriptional regulatory region continued to remain unmethylated in these donor CD8 T cells generated from a chronic infection. The observed maintenance of PD-1 surface expression and the demethylated PD-1 promoter were not a result of residual antigen in the recipient mice, because similar results were seen when chronic infection-induced effector cells were transferred into mice infected with a variant strain of LCMV (LCMV V35A) bearing a mutation in the cognate major histocompatibility complex class I (MHC-I) epitope that is recognized by the donor CD8 T cells. Importantly, the maintenance of PD-1 promoter demethylation in memory CD8 T cells was coupled with impaired clonal expansion and higher PD-1 re-expression upon secondary challenge. These data show that the imprinting of the epigenetic program of the inhibitory receptor PD-1 occurs during the effector phase of chronic viral infection. IMPORTANCE: Since PD-1 is a major inhibitory receptor regulating T cell dysfunction during chronic viral infection and cancers, a better understanding of the mechanisms that regulate PD-1 expression is important. In this work, we demonstrate that the PD-1 epigenetic program in antigen-specific CD8 T cells is fixed during the priming phase of chronic infection.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27466420      PMCID: PMC5021389          DOI: 10.1128/JVI.00798-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.

Authors:  Ben Youngblood; Kenneth J Oestreich; Sang-Jun Ha; Jaikumar Duraiswamy; Rama S Akondy; Erin E West; Zhengyu Wei; Peiyuan Lu; James W Austin; James L Riley; Jeremy M Boss; Rafi Ahmed
Journal:  Immunity       Date:  2011-09-23       Impact factor: 31.745

2.  Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection.

Authors:  Jill M Angelosanto; Shawn D Blackburn; Alison Crawford; E John Wherry
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

3.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  In vivo selection of a lymphocytic choriomeningitis virus variant that affects recognition of the GP33-43 epitope by H-2Db but not H-2Kb.

Authors:  M T Puglielli; A J Zajac; R G van der Most; J L Dzuris; A Sette; J D Altman; R Ahmed
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection.

Authors:  Matthew M Staron; Simon M Gray; Heather D Marshall; Ian A Parish; Jonathan H Chen; Curtis J Perry; Guoliang Cui; Ming O Li; Susan M Kaech
Journal:  Immunity       Date:  2014-11-13       Impact factor: 31.745

6.  Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection.

Authors:  Scott N Mueller; Mehrdad Matloubian; Daniel M Clemens; Arlene H Sharpe; Gordon J Freeman; Shivaprakash Gangappa; Christian P Larsen; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-18       Impact factor: 11.205

7.  Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1.

Authors:  Shinichiro Fuse; Ching-Yi Tsai; Michael J Molloy; S Rameeza Allie; Weijun Zhang; Hideo Yagita; Edward J Usherwood
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

8.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

9.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

Authors:  Shawn D Blackburn; Haina Shin; W Nicholas Haining; Tao Zou; Creg J Workman; Antonio Polley; Michael R Betts; Gordon J Freeman; Dario A A Vignali; E John Wherry
Journal:  Nat Immunol       Date:  2008-11-30       Impact factor: 25.606

10.  Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection.

Authors:  Peiyuan Lu; Benjamin A Youngblood; James W Austin; Ata Ur Rasheed Mohammed; Royce Butler; Rafi Ahmed; Jeremy M Boss
Journal:  J Exp Med       Date:  2014-03-03       Impact factor: 14.307

View more
  36 in total

Review 1.  Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.

Authors:  Hazem E Ghoneim; Anthony E Zamora; Paul G Thomas; Ben A Youngblood
Journal:  Trends Mol Med       Date:  2016-11-04       Impact factor: 11.951

2.  Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells.

Authors:  Sisi Deng; Zhichen Sun; Jian Qiao; Yong Liang; Longchao Liu; Chunbo Dong; Aijun Shen; Yang Wang; Hong Tang; Yang-Xin Fu; Hua Peng
Journal:  JCI Insight       Date:  2020-04-09

Review 3.  Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy.

Authors:  Caitlin C Zebley; Stephen Gottschalk; Ben Youngblood
Journal:  Trends Immunol       Date:  2020-07-02       Impact factor: 16.687

4.  Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells.

Authors:  Sema Kurtulus; Asaf Madi; Giulia Escobar; Max Klapholz; Jackson Nyman; Elena Christian; Mathias Pawlak; Danielle Dionne; Junrong Xia; Orit Rozenblatt-Rosen; Vijay K Kuchroo; Aviv Regev; Ana C Anderson
Journal:  Immunity       Date:  2019-01-08       Impact factor: 31.745

Review 5.  Precursor exhausted T cells: key to successful immunotherapy?

Authors:  Axel Kallies; Dietmar Zehn; Daniel T Utzschneider
Journal:  Nat Rev Immunol       Date:  2019-10-07       Impact factor: 53.106

Review 6.  Transcriptional and epigenetic regulation of T cell hyporesponsiveness.

Authors:  Renata M Pereira; Patrick G Hogan; Anjana Rao; Gustavo J Martinez
Journal:  J Leukoc Biol       Date:  2017-06-12       Impact factor: 4.962

Review 7.  Epigenetic mechanisms of tumor resistance to immunotherapy.

Authors:  Natalia Arenas-Ramirez; Dilara Sahin; Onur Boyman
Journal:  Cell Mol Life Sci       Date:  2018-08-23       Impact factor: 9.261

Review 8.  Targeting the epigenetic regulation of antitumour immunity.

Authors:  Simon J Hogg; Paul A Beavis; Mark A Dawson; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2020-09-14       Impact factor: 84.694

Review 9.  Immune checkpoint blockade in infectious diseases.

Authors:  Michelle N Wykes; Sharon R Lewin
Journal:  Nat Rev Immunol       Date:  2017-10-09       Impact factor: 53.106

10.  DNA hypermethylation during tuberculosis dampens host immune responsiveness.

Authors:  Andrew R DiNardo; Kimal Rajapakshe; Tomoki Nishiguchi; Sandra L Grimm; Godwin Mtetwa; Qiniso Dlamini; Jaqueline Kahari; Sanjana Mahapatra; Alexander Kay; Gugu Maphalala; Emily M Mace; George Makedonas; Jeffrey D Cirillo; Mihai G Netea; Reinout van Crevel; Cristian Coarfa; Anna M Mandalakas
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.